Patient-derived xenograft models in cancer therapy: technologies and applications
Patient-derived xenograft (PDX) models, in which tumor tissues from patients are implanted
into immunocompromised or humanized mice, have shown superiority in recapitulating the …
into immunocompromised or humanized mice, have shown superiority in recapitulating the …
Radiotherapy in combination with CD47 blockade elicits a macrophage-mediated abscopal effect
Radiation therapy is a mainstay of cancer treatment but does not always lead to complete
tumor regression. Here we combine radiotherapy with blockade of the 'don't-eat-me'cell …
tumor regression. Here we combine radiotherapy with blockade of the 'don't-eat-me'cell …
Potent molecular-targeted therapies for gastro-entero-pancreatic neuroendocrine carcinoma
Neuroendocrine neoplasms (NENs), which are characterized by neuroendocrine
differentiation, can arise in various organs. NENs have been divided into well-differentiated …
differentiation, can arise in various organs. NENs have been divided into well-differentiated …
KDM6A epigenetically regulates subtype plasticity in small cell lung cancer
Small cell lung cancer (SCLC) exists broadly in four molecular subtypes: ASCL1,
NEUROD1, POU2F3 and Inflammatory. Initially, SCLC subtypes were thought to be mutually …
NEUROD1, POU2F3 and Inflammatory. Initially, SCLC subtypes were thought to be mutually …
Extrachromosomal DNA amplification contributes to small cell lung cancer heterogeneity and is associated with worse outcomes
Small-cell lung cancer (SCLC) is an aggressive neuroendocrine lung cancer. Oncogenic
MYC amplifications drive SCLC heterogeneity, but the genetic mechanisms of MYC …
MYC amplifications drive SCLC heterogeneity, but the genetic mechanisms of MYC …
Integrative analysis of a large real-world cohort of small cell lung cancer identifies distinct genetic subtypes and insights into histologic transformation
Small cell lung cancer (SCLC) is a recalcitrant neuroendocrine carcinoma with dismal
survival outcomes. A major barrier in the field has been the relative paucity of human tumors …
survival outcomes. A major barrier in the field has been the relative paucity of human tumors …
Immune heterogeneity in small-cell lung cancer and vulnerability to immune checkpoint blockade
Summary Atezolizumab (anti-PD-L1), combined with carboplatin and etoposide (CE), is now
a standard of care for extensive-stage small-cell lung cancer (ES-SCLC). A clearer …
a standard of care for extensive-stage small-cell lung cancer (ES-SCLC). A clearer …
Berzosertib plus topotecan vs topotecan alone in patients with relapsed small cell lung cancer: a randomized clinical trial
N Takahashi, Z Hao, LC Villaruz, J Zhang, J Ruiz… - JAMA …, 2023 - jamanetwork.com
Importance Patients with relapsed small cell lung cancer (SCLC), a high replication stress
tumor, have poor prognoses and few therapeutic options. A phase 2 study showed antitumor …
tumor, have poor prognoses and few therapeutic options. A phase 2 study showed antitumor …
Histopathology images-based deep learning prediction of prognosis and therapeutic response in small cell lung cancer
Y Zhang, Z Yang, R Chen, Y Zhu, L Liu, J Dong… - NPJ digital …, 2024 - nature.com
Small cell lung cancer (SCLC) is a highly aggressive subtype of lung cancer characterized
by rapid tumor growth and early metastasis. Accurate prediction of prognosis and …
by rapid tumor growth and early metastasis. Accurate prediction of prognosis and …
Molecular phenotyping of small cell lung cancer using targeted cfDNA profiling of transcriptional regulatory regions
JB Hiatt, AL Doebley, HU Arnold, M Adil… - Science …, 2024 - science.org
We report an approach for cancer phenotyping based on targeted sequencing of cell-free
DNA (cfDNA) for small cell lung cancer (SCLC). In SCLC, differential activation of …
DNA (cfDNA) for small cell lung cancer (SCLC). In SCLC, differential activation of …